Pathway Genomics Corporation (Pathway) acknowledges the guidelines published jointly by the American Society of Human Genetics (ASHG) and the American College of Medical Genetics (ACMG) regarding the genetic testing of children and adolescents. The ASHG/ACMG report states "decisions about genetic testing in children should be based on an assessment of the possible benefits and harms that may be associated with the tests".

The policy of Pathway is that the primary role of genetic testing of children is to provide information that would further medical treatment during childhood years. These are conditions that typically present prior to age 18, for which early intervention and surveillance options exist, and for which early diagnosis promotes better treatment and/or management of symptoms. Testing may determine whether children are at increased risk for a specific list of conditions and how children might respond to certain types of drugs or medications. Genetic testing is not recommended for children if the medical or psychosocial benefits will not be benefits will not be useful until the child reaches adulthood. This scenario may include testing for diseases which occur during adulthood and if the child is a carrier of one or more genetic mutations or changes when there is no agreed upon preventive treatment in childhood. For adolescents, the benefits of genetic testing are more likely to be psychosocial rather than physical. Evaluation of the impact of genetic testing of adolescents requires an assessment of the competence and maturity of the adolescent to receive that information and his/her ability to provide informed consent.

For children under age 18 who are tested by Pathway, results reported to the parents will include only information relevant to the medical care of that child during childhood. When the tested child reaches age 18, they may request and receive full information about their genetic test.